Clinical Trial

Universal CAR-T Cell Therapy for Refractory Lupus Nephritis

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 8, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
This investigator-initiated trial aims to assess the efficacy and safety of combination therapy using universal CAR-T cells targeting BCMA and CD19 in refractory lupus nephritis.
Trial Details
NCT Number NCT06681337
Lead Sponsor Bioray Laboratories
Collaborators: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions Lupus Nephritis
Enrollment 10 participants
Start Date 2024-11-25
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2024-11-08